Tvardi Therapeutics Reports Phase 1 Results for TTI-109
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Source: NASDAQ.COM
- Drug Design Validation: Tvardi Therapeutics' TTI-109, a phosphate prodrug of TTI-101, rapidly converts to its active form within two hours, achieving plasma levels nearly identical to TTI-101, validating the prodrug strategy's effectiveness and feasibility.
- Significantly Improved Tolerability: Compared to TTI-101, TTI-109 shows a marked reduction in diarrhea event duration from 3.35 days to 0.46 days, indicating better tolerability in clinical applications, which may enhance patient adherence to treatment.
- Positive Pharmacodynamic Signals: The study reveals that TTI-109 reduces STAT3-driven immune cell populations by up to 60% over 21 days of repeat dosing, providing strong support for its potential in treating related diseases, particularly dermatologic and gastrointestinal conditions.
- Future Research Plans: Tvardi intends to advance TTI-109 into Phase 2 studies targeting STAT3-driven dermatologic and gastrointestinal diseases, contingent on securing additional funding, demonstrating the company's ongoing commitment and strategic direction in drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVRD
Wall Street analysts forecast TVRD stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.010
Low
4.00
Averages
9.00
High
15.00
Current: 2.010
Low
4.00
Averages
9.00
High
15.00
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tvardi Therapeutics Reports Phase 1 Results for TTI-109
- Drug Design Validation: Tvardi Therapeutics' TTI-109, a phosphate prodrug of TTI-101, rapidly converts to its active form within two hours, achieving plasma levels nearly identical to TTI-101, validating the prodrug strategy's effectiveness and feasibility.
- Significantly Improved Tolerability: Compared to TTI-101, TTI-109 shows a marked reduction in diarrhea event duration from 3.35 days to 0.46 days, indicating better tolerability in clinical applications, which may enhance patient adherence to treatment.
- Positive Pharmacodynamic Signals: The study reveals that TTI-109 reduces STAT3-driven immune cell populations by up to 60% over 21 days of repeat dosing, providing strong support for its potential in treating related diseases, particularly dermatologic and gastrointestinal conditions.
- Future Research Plans: Tvardi intends to advance TTI-109 into Phase 2 studies targeting STAT3-driven dermatologic and gastrointestinal diseases, contingent on securing additional funding, demonstrating the company's ongoing commitment and strategic direction in drug development.
See More
Universe Pharma Acquires Patent Portfolio, Shares Surge
- Strategic Acquisition: Universe Pharmaceuticals Inc. (UPC) announced a $10.75 million acquisition of 100% of Best Praise International Limited, securing five Chinese patents covering elderly healthcare and cognitive health, with the deal expected to close in Q3 2026, significantly enhancing its competitive edge in the pharmaceutical market.
- Stock Surge: Following the acquisition announcement, UPC's shares soared over 300% to close at $12.18 on Monday, reflecting strong market confidence in its future growth potential and solidifying its position in the Chinese pharmaceutical industry.
- PIPE Financing: Decoy Therapeutics Inc. (DCOY) announced a PIPE financing of up to $21 million, leading to a 70% stock price increase, which includes $3.5 million in upfront proceeds, indicating strong market recognition of its funding capabilities and expected support for future R&D.
- Exploring Business Sale: QuidelOrtho Corp. (QDEL) shares rose over 30% as it explores the sale of its point-of-care testing business for approximately $1.5 billion, attracting interest from several private equity firms, which could provide significant capital inflow to support its strategic transformation.
See More
Tvardi Reports Clinical Progress on TTI-109 Inhibitor
- TTI-109 Study Progress: Tvardi is conducting a healthy volunteer study for TTI-109, with topline data expected in June 2026, which will inform future clinical development strategies and enhance the company's competitive edge in the STAT3 inhibitor market.
- TTI-101 Clinical Trials: The Phase 1b/2 trial of TTI-101 for hepatocellular carcinoma is on track to report topline results in the second half of 2026, with prior interim findings indicating clinically meaningful activity across various treatment settings, potentially opening new market opportunities for the company.
- Financial Status Improvement: Research and development expenses for Q1 2026 were $4.9 million, up from $3.1 million in Q1 2025, primarily due to increased costs associated with TTI-109 development, reflecting the company's ongoing investment in advancing its product pipeline.
- Cash Flow Outlook: As of March 31, 2026, Tvardi reported cash and short-term investments of $25 million, which is expected to be sufficient to fund operations through Q4 2026, ensuring adequate liquidity ahead of clinical readouts and boosting investor confidence.
See More
Tvardi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Tvardi Therapeutics reported a Q1 GAAP EPS of -$0.73, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $25.0 million, down from $30.8 million as of December 31, 2025, reflecting increased liquidity pressure.
- Funding Strategy: Tvardi anticipates that its current cash runway is sufficient to fund operations through clinical readouts and into Q4 2026, indicating a cautious approach to financial management amid future challenges.
- Market Outlook: Despite financial pressures, Tvardi is actively advancing clinical trials, and successful clinical readouts could present new growth opportunities, enhancing the company's competitive position in the market.
See More
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
Tvardi Therapeutics Reports Phase 1 Results for TTI-109
- Drug Design Validation: Tvardi Therapeutics' TTI-109, a phosphate prodrug of TTI-101, rapidly converts to its active form within two hours, achieving plasma levels nearly identical to TTI-101, validating the prodrug strategy's effectiveness and feasibility.
- Significantly Improved Tolerability: Compared to TTI-101, TTI-109 shows a marked reduction in diarrhea event duration from 3.35 days to 0.46 days, indicating better tolerability in clinical applications, which may enhance patient adherence to treatment.
- Positive Pharmacodynamic Signals: The study reveals that TTI-109 reduces STAT3-driven immune cell populations by up to 60% over 21 days of repeat dosing, providing strong support for its potential in treating related diseases, particularly dermatologic and gastrointestinal conditions.
- Future Research Plans: Tvardi intends to advance TTI-109 into Phase 2 studies targeting STAT3-driven dermatologic and gastrointestinal diseases, contingent on securing additional funding, demonstrating the company's ongoing commitment and strategic direction in drug development.
See More
Universe Pharma Acquires Patent Portfolio, Shares Surge
- Strategic Acquisition: Universe Pharmaceuticals Inc. (UPC) announced a $10.75 million acquisition of 100% of Best Praise International Limited, securing five Chinese patents covering elderly healthcare and cognitive health, with the deal expected to close in Q3 2026, significantly enhancing its competitive edge in the pharmaceutical market.
- Stock Surge: Following the acquisition announcement, UPC's shares soared over 300% to close at $12.18 on Monday, reflecting strong market confidence in its future growth potential and solidifying its position in the Chinese pharmaceutical industry.
- PIPE Financing: Decoy Therapeutics Inc. (DCOY) announced a PIPE financing of up to $21 million, leading to a 70% stock price increase, which includes $3.5 million in upfront proceeds, indicating strong market recognition of its funding capabilities and expected support for future R&D.
- Exploring Business Sale: QuidelOrtho Corp. (QDEL) shares rose over 30% as it explores the sale of its point-of-care testing business for approximately $1.5 billion, attracting interest from several private equity firms, which could provide significant capital inflow to support its strategic transformation.
See More
Tvardi Reports Clinical Progress on TTI-109 Inhibitor
- TTI-109 Study Progress: Tvardi is conducting a healthy volunteer study for TTI-109, with topline data expected in June 2026, which will inform future clinical development strategies and enhance the company's competitive edge in the STAT3 inhibitor market.
- TTI-101 Clinical Trials: The Phase 1b/2 trial of TTI-101 for hepatocellular carcinoma is on track to report topline results in the second half of 2026, with prior interim findings indicating clinically meaningful activity across various treatment settings, potentially opening new market opportunities for the company.
- Financial Status Improvement: Research and development expenses for Q1 2026 were $4.9 million, up from $3.1 million in Q1 2025, primarily due to increased costs associated with TTI-109 development, reflecting the company's ongoing investment in advancing its product pipeline.
- Cash Flow Outlook: As of March 31, 2026, Tvardi reported cash and short-term investments of $25 million, which is expected to be sufficient to fund operations through Q4 2026, ensuring adequate liquidity ahead of clinical readouts and boosting investor confidence.
See More
Tvardi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Tvardi Therapeutics reported a Q1 GAAP EPS of -$0.73, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $25.0 million, down from $30.8 million as of December 31, 2025, reflecting increased liquidity pressure.
- Funding Strategy: Tvardi anticipates that its current cash runway is sufficient to fund operations through clinical readouts and into Q4 2026, indicating a cautious approach to financial management amid future challenges.
- Market Outlook: Despite financial pressures, Tvardi is actively advancing clinical trials, and successful clinical readouts could present new growth opportunities, enhancing the company's competitive position in the market.
See More
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
